By Chris Wack


OncoSec Medical Inc. shares were up 25% to $3.48 after the company said it has entered into a collaboration and supply agreement with Merck & Co. to evaluate the combination of OncoSec's interleukin-12 Tavo with Merck's anti-cancer immunotherapy Keytruda in a global clinical trial.

Volume for the stock was 66.3 million shares at 12:15 p.m. ET, compared to its 65-day average volume of 228,000 shares. The stock has 39 million shares outstanding, with a public float of 16 million shares.

OncoSec said the planned Phase 3 trial would evaluate the overall survival of patients treated with Tavo and Keytruda versus standard of care in late-stage patients with metastatic melanoma who are refractory to immune checkpoint therapy.

Tavo has received fast-track designation from the U.S. Food and Drug Administration as a potentially first-in-class, intratumoral anti-cancer gene therapy that expresses IL-12 for the treatment of metastatic melanoma, following progression on Keytruda or Opdivo.

The new trial is intended to support accelerated approval by the U.S. FDA and/or serve as a pivotal study to support a full licensure, OncoSec said.

Under the terms of the agreement, each party will be responsible for its own internal costs, with OncoSec covering third-party costs.

The study intends to enroll 400 patients and is planned to be conducted in the U.S., Canada, the European Union and Australia.


Write to Chris Wack at


(END) Dow Jones Newswires

July 07, 2021 12:36 ET (16:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Merck Charts.